Mark Chess is the Managing Director of the Infinity Equity. He helped establish the FBR Infinity II Fund in 2001 and the world's first foreign currency fund in China in 2005 (Infinity-CSVC). Mr. Chess manages Infinity’s strategic relationships with institutions in the United States including the Infinity-NSF portfolio. Prior to Infinity, Mr. Chess was a director with Partners500, leading the company’s international business development. Mr. Chess graduated with a degree in Business Honors from the McCombs School of Business at the University of Texas at Austin.
Dr. Doron Gal
Dr. Gal serves as Director since November 2007. Dr. Gal also served as VP of Business Development, CEO and President of Kaiima. Previously, Dr. Gal was Senior Energy Consultant at Epsilon Investment House. Prior to that, Dr. Gal was an Adj. Lecturer on Energy and Geo-strategy at the Lauder School of Government, IDC Herzliya, a Senior Research Fellow (Energy) for the Institute for Policy and Strategy and was advising investment groups and government agencies. Dr. Gal was also President of Digigroups Corporation. Dr. Gal holds a Ph.D. in Geophysics from Stanford University.
Dr. Ganesh M. Kishore
Dr. Kishore (Kish) serves as a Director since 2012 and is a Managing Partner of Spruce Capital Partners LLC as well as a Director and CEO of The Malaysian Life Sciences Capital Fund. Previously, Kish served as the VP of Science & Technology and the Chief Biotechnology Officer of DuPont, where he also served as VP of technology for DuPont’s Agriculture & Nutrition division. Dr. Kishore started his career at Monsanto serving a Senior Research Biochemist. At Monsanto, Dr. Kishore won the Queeny Award, a prize given by Monsanto in recognition of his contributions to the development of Roundup Ready technology. In 2015, Dr. Kishore was named to the WorldVIEW 100 list as one of the most influential people in biotech today. In 2016, The Biotechnology Innovation Organization (BIO) presented Dr. Kishore the first annual BIO Leadership and Legacy Award.
Dr. Raoul Oberman
Dr. Raoul Oberman serves as a Director since 2014. Prior to this, Dr. Oberman spent 23 years with McKinsey in various positions in Korea, Germany and the Netherlands. In his most recent position with McKinsey, Dr. Oberman was Chairman of McKinsey PT Indonesia. Previously, Dr. Oberman was an associate with Deutsche Bank.
Jason Wong serves as Director since 2013, and is the Managing Director of Horizons Ventures, a private investment vehicle that manages the technology investments of Mr. Li Ka Shing and is based in Hong Kong. Mr. Wong also sits on the boards of some of Horizons’ other portfolio companies such as Waze, Onavo, Fixmo, Cortica and CorePhotonics. Mr. Wong holds a B.Eng. in Mechanical Engineering from the University College London in the United Kingdom.
Dr. Benny Zeevi
Dr. Benny Zeevi serves as a Director at Kaiima since 2007 and is a Managing General Partner in DFJ Tamir Fishman Venture and DFJ Tel Aviv Venture Partners, leading the fund’s Life Science and Cleantech investments. Dr. Zeevi is a physician specialized in interventional pediatric cardiology. Prior to joining DFJ TFV in 2003, Dr. Zeevi was the Vice President Business Development & Medical Director of Card Guard AG since 1998.
Ruzgar Barisik, Senior Investment Officer, IFC
Atsushi Mizuno, Investment Director, Mitsui Global Investment
Dr. Sass Somekh, Founder and Partner, Musea Ventures